Zinzino group revenue increased with a total of 24 %, compared with the previous year.

The revenue in May for Zinzino's sales markets increased by 23 % and amounted to SEK 172.3 (139.9) million. Faun Pharma's external sales increased by 31 % and amounted to SEK 9.2 (7.0) million. Overall, the Group increased revenues by 24 % to SEK 181.5 (146.9) million compared with the previous year.

Accumulated revenue for January - May 2024 increased by 21 % to SEK 802.2 (661.8) million.

Revenues were distributed as follows:

Regions,MSEK 24 23 Change YTD YTD 2023 Change
-May -May 2024
The Nordics 25.3 26,0 -3% 118.6 121.1 -2%
Central 49.2 34.2 44% 214.1 154.4 39%
Europe
East Europe 34.7 34.0 2% 159.5 157.1 2%
South & West 33.2 25.0 33% 130.2 89.6 45%
Europe
The Baltics 8.8 7.6 16% 40.8 35.7 14%
North 15.1 7,0 116% 65.8 32.4 103%
America
Asia-Pacific 4.7 4.7 0% 22.5 25.5 -12%
Africa 1.3 1.4               5.7 6.2               -8%
-7%
Zinzino 172.3 139.9 23% 757.2 622.0 22%
Faun Pharma 9.2 7.0 31% 45.0 39.8 13%
Zinzino 181.5 146.9 24% 802.2 661.8 21%
Group

Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Turkey
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge: marketing@zinzino.com

Certified Adviser: Carnegie Investment Bank AB (publ)